[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-001", "question": "A 34-year-old woman presents with 6 months of progressive bilateral hand weakness and numbness. She has a 15-year history of systemic lupus erythematosus treated with hydroxychloroquine and low-dose prednisone. Examination reveals symmetric weakness of finger abduction and adduction bilaterally, decreased sensation to pinprick over the ulnar aspect of both hands, and absent ulnar deep tendon reflexes. Nerve conduction studies show reduced compound muscle action potential amplitudes in bilateral ulnar nerves with conduction block at the elbow, prolonged distal motor latencies, and temporal dispersion. Anti-ganglioside antibodies are negative. CSF shows protein 85 mg/dL with 2 WBCs. Which of the following is the most likely diagnosis?", "options": ["Multifocal motor neuropathy with conduction block", "Chronic inflammatory demyelinating polyneuropathy", "Lupus-associated mononeuritis multiplex", "Lewis-Sumner syndrome", "Hereditary neuropathy with liability to pressure palsies"], "answer": "D", "answer_index": 3, "explanation": "Lewis-Sumner syndrome (multifocal acquired demyelinating sensory and motor neuropathy, MADSAM) is characterized by asymmetric sensorimotor involvement with demyelinating features including conduction block, distinguishing it from multifocal motor neuropathy (purely motor, anti-GM1 positive) and CIDP (symmetric). The presence of sensory symptoms and signs excludes MMN. Lupus mononeuritis multiplex typically shows axonal rather than demyelinating features. HNPP would show conduction abnormalities at typical compression sites without temporal dispersion.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let’s break this down:  \n\n- **History**: SLE for 15 years, on hydroxychloroquine and prednisone.  \n- **Symptoms**: Progressive bilateral hand weakness/numbness, symmetric finger abduction/adduction weakness, sensory loss in ulnar distribution bilaterally, absent ulnar reflexes.  \n- **NCS findings**: Reduced CMAP amplitudes in ulnar nerves, **conduction block at elbow**, prolonged distal motor latencies, temporal dispersion → all features of **demyelinating neuropathy with focal conduction block**.  \n- **Anti-ganglioside antibodies negative** → argues against multifocal motor neuropathy (MMN), which usually has no sensory involvement and positive GM1 antibodies in many cases.  \n- **CSF protein elevated** (85 mg/dL) with normal cell count → typical for chronic inflammatory demyelinating polyneuropathy (CIDP) but also seen in others.  \n- **Symmetry and bilaterality** → not typical for mononeuritis multiplex (asymmetric, multiple individual nerves affected stepwise) or HNPP (pressure palsies, episodic).  \n- **Lewis-Sumner syndrome** (multifocal acquired demyelinating sensory and motor neuropathy, MADSAM) is asymmetric initially, often starts in upper limbs, but here it’s symmetric from the start.  \n\nGiven **symmetric** sensorimotor polyneuropathy with demyelination features (conduction block, temporal dispersion, prolonged DML), elevated CSF protein, chronic progression, and no anti-ganglioside antibodies, the best fit is **chronic inflammatory demyelinating polyneuropathy (CIDP)**. CIDP can occur in SLE as a comorbid autoimmune neuropathy.  \n\nThe answer is B.  \n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-002", "question": "A 28-year-old woman at 32 weeks gestation presents with sudden onset severe headache, visual disturbances, and confusion. Blood pressure is 178/112 mmHg. Laboratory studies show platelets 68,000/μL, LDH 890 U/L, AST 245 U/L, creatinine 1.8 mg/dL, and peripheral smear with schistocytes. She receives magnesium sulfate and labetalol. Emergent cesarean delivery is performed. Postpartum day 3, despite delivery, her platelet count drops to 42,000/μL, creatinine rises to 2.9 mg/dL, and she develops new neurological symptoms. ADAMTS13 activity returns at 58%. Which additional finding would most strongly support initiating eculizumab therapy?", "options": ["Positive direct antiglobulin test", "Complement factor H mutation on genetic testing", "Elevated soluble fms-like tyrosine kinase-1 levels", "Low C3 with normal C4 levels", "Presence of anti-phospholipid antibodies"], "answer": "B", "answer_index": 1, "explanation": "This presentation of postpartum thrombotic microangiopathy not resolving after delivery with ADAMTS13 >10% suggests complement-mediated TMA (atypical HUS) rather than TTP or HELLP syndrome. Complement factor H mutation confirms complement dysregulation and strongly supports eculizumab (C5 inhibitor) therapy. Low C3 with normal C4 suggests alternative pathway activation but is nonspecific. Elevated sFlt-1 would suggest ongoing preeclampsia-related pathology. Positive DAT would suggest Evans syndrome, and anti-phospholipid antibodies suggest catastrophic APS, both requiring different management.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient has a presentation consistent with severe preeclampsia/HELLP syndrome, but postpartum worsening with neurological symptoms and schistocytes suggests possible thrombotic microangiopathy (TMA).  \nADAMTS13 activity of 58% (>10%) rules out typical thrombotic thrombocytopenic purpura (TTP).  \nIn the setting of pregnancy-related TMA that persists or worsens postpartum, atypical hemolytic uremic syndrome (aHUS) is a key consideration, which is driven by dysregulation of the alternative complement pathway.  \nEculizumab is a monoclonal antibody against C5 used in aHUS.  \nLow C3 with normal C4 suggests alternative complement pathway activation, supporting a diagnosis of aHUS rather than preeclampsia alone.  \n\nThe answer is D"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-003", "question": "A 52-year-old man with hypertrophic cardiomyopathy and an ICD presents with recurrent appropriate shocks for ventricular tachycardia despite maximum tolerated doses of metoprolol and disopyramide. Echocardiogram shows septal thickness of 22 mm, LVOT gradient of 85 mmHg at rest, and moderate mitral regurgitation with systolic anterior motion. Cardiac MRI demonstrates 18% late gadolinium enhancement predominantly in the septum. Coronary angiography is normal. Which intervention is most likely to reduce his arrhythmia burden?", "options": ["Alcohol septal ablation", "Surgical septal myectomy with mitral valve repair", "Catheter ablation of ventricular tachycardia", "Addition of amiodarone to current regimen", "Cardiac transplantation evaluation"], "answer": "B", "answer_index": 1, "explanation": "In HCM patients with significant LVOT obstruction, extensive LGE (>15%), and recurrent VT, surgical myectomy is preferred over alcohol septal ablation because ASA creates additional scar that may be proarrhythmic. Myectomy reduces obstruction and allows concomitant mitral valve repair for SAM-related MR. The extensive LGE indicates high arrhythmic substrate burden. VT ablation addresses the arrhythmia but not the underlying obstruction driving symptoms. Amiodarone adds toxicity risk without addressing mechanism. Transplant is premature given available surgical options.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has hypertrophic cardiomyopathy with significant LVOT obstruction (85 mmHg at rest), moderate mitral regurgitation due to systolic anterior motion, and recurrent ventricular tachycardia despite medical therapy.  \nAlcohol septal ablation could reduce the gradient but is less definitive for addressing mitral regurgitation and may not optimally reduce arrhythmia burden in someone with extensive septal scarring already (18% LGE).  \nSurgical septal myectomy with mitral valve repair directly relieves obstruction, treats the mitral regurgitation, and evidence suggests that in selected patients, myectomy can reduce ventricular arrhythmia burden, possibly by relieving ischemia and remodeling.  \nCatheter ablation for VT in HCM is challenging due to intramural circuits and is generally considered after other treatments.  \nAmiodarone could be added but is not an intervention and carries long-term toxicity risks.  \nTransplantation is premature before definitive septal reduction and mitral repair.  \n\nGiven the combination of drug-refractory VT, significant obstruction, and mitral regurgitation, the most appropriate intervention to address both symptoms and likely reduce arrhythmia is surgical myectomy with mitral valve repair.  \n\nThe answer is B"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-004", "question": "A 45-year-old woman with dermatomyositis diagnosed 8 months ago presents with progressive dyspnea. She was initially treated with high-dose prednisone and azathioprine with improvement in proximal muscle weakness. CT chest shows new ground-glass opacities with peripheral consolidation in lower lobes. Pulmonary function tests reveal FVC 58% predicted, DLCO 42% predicted. Bronchoalveolar lavage shows 35% lymphocytes. She tests positive for anti-MDA5 antibodies. Which treatment approach offers the best chance of halting disease progression?", "options": ["Increase prednisone and add mycophenolate mofetil", "Triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide", "Rituximab with continued azathioprine", "Nintedanib with continued current immunosuppression", "Plasma exchange followed by IVIG maintenance"], "answer": "B", "answer_index": 1, "explanation": "Anti-MDA5 dermatomyositis-associated rapidly progressive interstitial lung disease carries high mortality and requires aggressive upfront combination immunosuppression. Japanese and international experience supports triple therapy with high-dose corticosteroids, a calcineurin inhibitor (tacrolimus or cyclosporine), and cyclophosphamide as the most effective approach for halting progression. Single-agent additions or rituximab have shown inferior outcomes in this specific antibody subset. Nintedanib is antifibrotic, not immunosuppressive. Plasma exchange lacks evidence in this context.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has dermatomyositis with anti-MDA5 antibodies, which is strongly associated with rapidly progressive interstitial lung disease (RP-ILD) and has a high mortality.  \nIn anti-MDA5-positive dermatomyositis with progressive ILD despite initial immunosuppression, evidence supports aggressive early combination immunosuppression.  \nThe most effective regimen reported in studies, especially for severe or progressive cases, is **triple therapy with high-dose glucocorticoids, a calcineurin inhibitor (like tacrolimus or cyclosporin), and cyclophosphamide**. This approach has shown survival benefit in anti-MDA5-associated RP-ILD.  \n\nOther options are less effective as first-line for halting progression in this scenario:  \n- Mycophenolate mofetil (A) is often used but may not be rapid/strong enough alone.  \n- Rituximab (C) has a role but is often considered after or with calcineurin inhibitors in refractory cases.  \n- Nintedanib (D) is antifibrotic and may slow progression in fibrotic ILD but does not address acute inflammatory progression in RP-ILD as primary therapy.  \n- Plasma exchange/IVIG (E) may be adjunctive but not first-line for halting progression in anti-MDA5 disease.  \n\nThe answer is B"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-005", "question": "A 38-year-old man from Cambodia presents with 3 weeks of fever, headache, and altered mental status. CSF analysis shows opening pressure 32 cm H2O, WBC 180/μL (90% lymphocytes), protein 120 mg/dL, glucose 28 mg/dL (serum 110 mg/dL). India ink preparation shows encapsulated yeast. Cryptococcal antigen titer is 1:2048 in CSF. HIV testing is positive with CD4 count of 35 cells/μL. He is started on liposomal amphotericin B and flucytosine with daily therapeutic lumbar punctures. On day 10, repeat lumbar puncture shows opening pressure 38 cm H2O, CSF WBC 420/μL (85% lymphocytes), protein 180 mg/dL, and cryptococcal antigen titer 1:1024. He has worsening headache and new sixth nerve palsy. What is the most appropriate next step?", "options": ["Add dexamethasone for paradoxical immune reconstitution inflammatory syndrome", "Switch to high-dose fluconazole for amphotericin resistance", "Place a ventriculoperitoneal shunt for refractory elevated intracranial pressure", "Continue current antifungal therapy with more aggressive CSF drainage", "Initiate antiretroviral therapy immediately to improve immune function"], "answer": "D", "answer_index": 3, "explanation": "The rising CSF pleocytosis with persistent elevated opening pressure despite treatment represents ongoing cryptococcal meningitis with inadequate pressure management rather than treatment failure or IRIS (patient not yet on ART). The antigen titer is decreasing appropriately. Management requires more aggressive CSF drainage-either more frequent LPs or temporary lumbar drain placement. Corticosteroids are contraindicated in cryptococcal meningitis (increased mortality in COAT trial). VPS is reserved for truly refractory cases after optimizing medical management. Early ART initiation increases IRIS risk and mortality when started before 4-6 weeks of antifungal therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has cryptococcal meningitis with elevated intracranial pressure (ICP) that is worsening despite antifungal therapy and daily therapeutic lumbar punctures.  \nNew sixth nerve palsy and headache progression indicate persistently high ICP, which is the main immediate threat.  \nIn cryptococcal meningitis with refractory elevated ICP, placement of a ventriculoperitoneal shunt or lumbar drain is indicated when repeated LPs fail to control symptoms.  \nAdding steroids is not recommended in HIV-associated cryptococcal meningitis unless it is clearly immune reconstitution inflammatory syndrome (IRIS) after ART initiation, but ART has not been started yet.  \nSwitching antifungals is not indicated because antigen titer is decreasing (1:2048 to 1:1024), suggesting therapy is effective against the fungus.  \nStarting ART now risks worsening IRIS and should be delayed until fungal control is achieved (usually after 2–5 weeks of antifungal therapy).  \nContinuing current management with more aggressive CSF drainage could mean serial LPs or a drain, but given failure of daily LPs and worsening neurology, a more definitive intervention like shunt is appropriate.  \n\nThe answer is C"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-006", "question": "A 67-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab develops progressive cognitive decline over 4 months. MRI brain shows multifocal white matter lesions without enhancement or mass effect. CSF shows 8 WBCs (all lymphocytes), protein 62 mg/dL, and negative routine cultures. JC virus PCR in CSF is positive with 850 copies/mL. Adalimumab is discontinued. Three weeks later, she develops new right hemiparesis and worsening confusion. Repeat MRI shows enlargement of lesions with new peripheral enhancement and edema. CSF now shows 45 WBCs (predominantly lymphocytes). What is the most appropriate management?", "options": ["Restart adalimumab to suppress destructive inflammation", "Initiate high-dose corticosteroids", "Begin cidofovir and cytarabine combination therapy", "Administer pembrolizumab to enhance JC virus clearance", "Perform brain biopsy to exclude CNS lymphoma"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed immune reconstitution inflammatory syndrome (IRIS) following discontinuation of immunosuppression in the setting of PML. The new enhancement, edema, and increased CSF pleocytosis after stopping adalimumab are classic for PML-IRIS. High-dose corticosteroids are indicated to reduce the inflammatory response that, while representing immune recovery, can cause significant neurological damage. Restarting immunosuppression would be counterproductive. Cidofovir/cytarabine lack efficacy in PML. Pembrolizumab is used in refractory PML without immune reconstitution, not IRIS. Biopsy is unnecessary given confirmed JC virus and classic IRIS presentation.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has progressive multifocal leukoencephalopathy (PML) due to JC virus, likely related to immunosuppression from adalimumab (a TNF inhibitor). After stopping adalimumab, she developed immune reconstitution inflammatory syndrome (IRIS), as evidenced by clinical worsening, new enhancement on MRI, and increased CSF lymphocytes.  \n\nThe appropriate management for PML-IRIS is to treat the inflammatory component with **high-dose corticosteroids** to reduce immune-mediated brain injury while the immune system recovers.  \n\nThe answer is B"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-007", "question": "A 29-year-old woman presents with 2 years of recurrent oral ulcers, genital ulcers, and bilateral anterior uveitis. She now develops sudden painless vision loss in her right eye. Examination reveals visual acuity of hand motion OD and 20/25 OS. Fundoscopy of the right eye shows diffuse retinal whitening with cherry-red spot and box-carring in retinal arterioles. Fluorescein angiography confirms central retinal artery occlusion. HLA-B51 is positive. Pathergy test is negative. What is the most appropriate immediate intervention to prevent contralateral involvement?", "options": ["High-dose intravenous methylprednisolone alone", "Infliximab infusion", "Combination of high-dose corticosteroids with cyclosporine", "Combination of high-dose corticosteroids with infliximab or adalimumab", "Anterior chamber paracentesis with ocular massage"], "answer": "D", "answer_index": 3, "explanation": "This patient has Behçet disease with ocular involvement including the devastating complication of retinal artery occlusion from retinal vasculitis. Immediate aggressive immunosuppression is critical to prevent bilateral blindness. Current evidence supports combination therapy with high-dose corticosteroids plus a TNF-alpha inhibitor (infliximab or adalimumab) as the most effective approach for severe ocular Behçet. Corticosteroids alone or with cyclosporine are insufficient for this severity. Anterior chamber paracentesis addresses embolic CRAO, not inflammatory vasculitic occlusion. The goal is preventing contralateral involvement through rapid inflammation control.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient has Behçet’s disease (recurrent oral/genital ulcers, uveitis, HLA-B51 positive) with acute central retinal artery occlusion (CRAO) in one eye and risk of contralateral involvement.  \n\nIn Behçet’s with posterior segment involvement (especially retinal vasculitis or vascular occlusion), guidelines recommend aggressive immunosuppression to prevent bilateral vision loss. High-dose IV corticosteroids alone are insufficient; combination therapy with a biologic anti-TNF agent (infliximab or adalimumab) plus corticosteroids is the standard for severe ocular Behçet’s to rapidly control inflammation and prevent contralateral eye damage.  \n\nAnterior chamber paracentesis with ocular massage (E) is sometimes used in isolated non-arteritic CRAO but does not treat the underlying vasculitis in Behçet’s. Cyclosporine (C) is used in Behçet’s but acts slower than anti-TNF for acute severe sight-threatening disease. Infliximab alone (B) without corticosteroids is not the typical initial acute protocol.  \n\nThe most appropriate immediate intervention to prevent contralateral involvement here is **combination high-dose corticosteroids with infliximab or adalimumab**.  \n\nThe answer is D"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-008", "question": "A 41-year-old man with no significant medical history presents with 6 weeks of progressive bilateral lower extremity weakness and paresthesias. He reports a diarrheal illness 8 weeks ago. Examination shows 3/5 strength in hip flexors, 4/5 in knee extensors, 4-/5 in ankle dorsiflexors bilaterally, absent deep tendon reflexes, and decreased vibration sense to the knees. Nerve conduction studies show reduced CMAP amplitudes with normal conduction velocities and no conduction block. Needle EMG shows active denervation in distal leg muscles. CSF protein is 95 mg/dL with 1 WBC. Anti-GM1 IgG antibodies are strongly positive. Despite 5 days of IVIG, he continues to worsen with new respiratory compromise requiring intubation. What is the next best step in management?", "options": ["Repeat IVIG course immediately", "Initiate plasma exchange", "Add high-dose intravenous methylprednisolone", "Begin eculizumab therapy", "Administer second IVIG course after 4-week interval"], "answer": "B", "answer_index": 1, "explanation": "This patient has acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome, evidenced by pure motor axonal pattern on NCS, anti-GM1 antibodies, and preceding Campylobacter-like illness. When patients fail to respond to initial IVIG and continue deteriorating, plasma exchange is the appropriate next step as it works through a different mechanism (antibody removal vs. immunomodulation). The treatments are not synergistic when given together but can be used sequentially. Corticosteroids are ineffective in GBS. Eculizumab has shown promise in refractory cases but is not yet standard of care. Waiting 4 weeks for repeat IVIG is inappropriate in a deteriorating patient.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has Guillain-Barré syndrome (GBS), likely acute motor axonal neuropathy (AMAN) variant given preceding diarrheal illness, pure motor/sensory findings, anti-GM1 antibodies, and electrophysiology showing axonal features without demyelination.  \n\nHe is progressing despite IVIG and now has respiratory failure. In GBS that worsens after initial IVIG, guidelines recommend either a second course of IVIG or switching to plasma exchange (PLEX). However, when a patient deteriorates rapidly with respiratory compromise soon after IVIG, plasma exchange is often preferred because it can remove antibodies and other factors, and there is no waiting period for a repeat IVIG course.  \n\nOption A (repeat IVIG immediately) is less supported because he just finished a 5-day course and is worsening; immediate repeat is not standard.  \nOption C (high-dose steroids) is not recommended in GBS—steroids alone are ineffective.  \nOption D (eculizumab) is used in refractory GBS in some recent trials but is not yet standard first-line rescue.  \nOption E (IVIG after 4 weeks) is too delayed given acute deterioration.  \n\nThus, the next best step is **initiate plasma exchange**.  \n\nThe answer is B"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-009", "question": "A 55-year-old woman with mechanical mitral valve replacement on warfarin presents with acute onset aphasia and right hemiplegia. Symptoms began 90 minutes ago. CT head shows no hemorrhage. CT angiography reveals left M1 occlusion. INR is 2.8. CT perfusion shows large penumbra with small core infarct (ASPECTS 8). Blood pressure is 165/95 mmHg. What is the most appropriate next step?", "options": ["Administer IV alteplase followed by endovascular thrombectomy", "Proceed directly to endovascular thrombectomy without IV thrombolysis", "Reverse anticoagulation with 4-factor PCC then administer IV alteplase", "Administer idarucizumab followed by IV alteplase", "Medical management only with blood pressure optimization"], "answer": "B", "answer_index": 1, "explanation": "In patients with acute ischemic stroke on therapeutic anticoagulation (INR >1.7), IV thrombolysis is contraindicated due to bleeding risk. However, mechanical thrombectomy is not contraindicated and should be pursued emergently in patients with large vessel occlusion and favorable perfusion imaging (large penumbra, small core). Reversing anticoagulation to give tPA adds delay and the combination increases bleeding risk. Idarucizumab reverses dabigatran, not warfarin. Medical management alone would result in completed large territory infarction given the M1 occlusion. Direct thrombectomy offers the best risk-benefit profile.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has an acute ischemic stroke with a large vessel occlusion and a favorable penumbra, making reperfusion therapy urgent. However, she is on warfarin with an INR of 2.8, which is above the typical thrombolysis cutoff (INR ≤1.7). IV alteplase is contraindicated with INR >1.7. Reversing anticoagulation before alteplase (option C) is not standard and delays therapy; guidelines recommend proceeding directly to endovascular thrombectomy (which can be done with INR up to 3.0 safely) and avoiding alteplase. Idarucizumab (option D) is for dabigatran reversal, not warfarin.  \n\nThe most appropriate next step is to proceed directly to endovascular thrombectomy without IV thrombolysis.  \n\nThe answer is B"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-010", "question": "A 33-year-old woman with no prior cardiac history presents with progressive exertional dyspnea over 3 months. She delivered her third child 5 months ago. Echocardiogram shows left ventricular ejection fraction of 25%, LV end-diastolic diameter of 62 mm, moderate functional mitral regurgitation, and no thrombus. BNP is 1,850 pg/mL. She is started on guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Genetic testing reveals a truncating variant in the TTN gene. At 6-month follow-up, LVEF has improved to 40% but remains below normal. Which factor most strongly predicts her likelihood of complete LV recovery?", "options": ["Absence of late gadolinium enhancement on cardiac MRI", "Normalization of BNP levels", "Presence of the TTN truncating variant", "Baseline LVEF above 30%", "Multiparity status"], "answer": "A", "answer_index": 0, "explanation": "In peripartum cardiomyopathy, the absence of late gadolinium enhancement (LGE) on cardiac MRI is the strongest predictor of complete LV recovery, indicating absence of irreversible myocardial fibrosis. TTN truncating variants are actually associated with incomplete recovery and persistent LV dysfunction in PPCM, making option C incorrect. While BNP normalization and higher baseline LVEF are favorable, they are less predictive than LGE status. Multiparity is a risk factor for developing PPCM but does not predict recovery. LGE represents scar that cannot recover regardless of optimal medical therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The absence of late gadolinium enhancement (LGE) on cardiac MRI indicates a non‑ischemic, non‑fibrotic substrate, which is strongly associated with reversible myocardial dysfunction and a higher likelihood of complete recovery in dilated cardiomyopathy, including peripartum cardiomyopathy.  \n\nWhile normalization of BNP and higher baseline LVEF can be favorable, LGE absence is the most robust predictor of LV functional recovery in this context. The TTN variant suggests a genetic predisposition but does not preclude recovery, and multiparity is not a strong independent predictor.  \n\nThe answer is A"}]